Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells $97,440.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 16,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director owned 126,500 shares in the company, valued at approximately $770,385. The trade was a 11.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $6.18 on Monday. The company has a market cap of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The company’s 50-day moving average price is $6.10 and its 200 day moving average price is $6.59. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on XERS shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.80.

Institutional Trading of Xeris Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in XERS. Royal Bank of Canada increased its position in shares of Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after acquiring an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after acquiring an additional 3,594 shares in the last quarter. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after acquiring an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after acquiring an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP purchased a new position in shares of Xeris Biopharma in the first quarter worth approximately $170,000. 42.75% of the stock is currently owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.